HRMY
Price:
$35.59
Market Cap:
$2.02B
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.[Read more]
Industry
Biotechnology
IPO Date
2020-08-19
Stock Exchange
NASDAQ
Ticker
HRMY
According to Harmony Biosciences Holdings, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 18.25. This represents a change of -8.68% compared to the average of 19.99 of the last 4 quarters.
The mean historical PE Ratio of Harmony Biosciences Holdings, Inc. over the last ten years is 0.59. The current 18.25 PE Ratio has changed 309.69% with respect to the historical average. Over the past ten years (40 quarters), HRMY's PE Ratio was at its highest in in the September 2020 quarter at 130.14. The PE Ratio was at its lowest in in the June 2020 quarter at -21582.50.
Average
0.59
Median
-0.00
Minimum
-45.68
Maximum
70.91
Discovering the peaks and valleys of Harmony Biosciences Holdings, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 165.97%
Maximum Annual PE Ratio = 70.91
Minimum Annual Increase = -278.79%
Minimum Annual PE Ratio = -45.68
Year | PE Ratio | Change |
---|---|---|
2023 | 14.91 | -17.03% |
2022 | 17.97 | -74.66% |
2021 | 70.91 | -278.79% |
2020 | -39.66 | 165.97% |
2019 | -14.91 | -67.35% |
The current PE Ratio of Harmony Biosciences Holdings, Inc. (HRMY) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
34.59
5-year avg
9.84
10-year avg
0.59
Harmony Biosciences Holdings, Inc.’s PE Ratio is greater than Keros Therapeutics, Inc. (-11.28), greater than Janux Therapeutics, Inc. (-51.01), less than Fennec Pharmaceuticals Inc. (54.24), greater than Edgewise Therapeutics, Inc. (-14.14), greater than Pliant Therapeutics, Inc. (-4.19), greater than Syndax Pharmaceuticals, Inc. (-6.17), greater than Revolution Medicines, Inc. (-13.31), greater than Viridian Therapeutics, Inc. (-3.95), greater than Inozyme Pharma, Inc. (-3.48), greater than Ventyx Biosciences, Inc. (-0.89), greater than Nuvalent, Inc. (-32.10), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than Travere Therapeutics, Inc. (-5.83), greater than Structure Therapeutics Inc. (-18.15), greater than Replimune Group, Inc. (-3.26), greater than Nuvectis Pharma, Inc. (-4.95), greater than Lyra Therapeutics, Inc. (-0.18), greater than Kronos Bio, Inc. (-0.58), greater than Gossamer Bio, Inc. (-2.55), greater than IDEAYA Biosciences, Inc. (-18.36), greater than Protagonist Therapeutics, Inc. (14.97), greater than Verona Pharma plc (-17.02),
Company | PE Ratio | Market cap |
---|---|---|
-11.28 | $1.97B | |
-51.01 | $2.15B | |
54.24 | $144.76M | |
-14.14 | $1.64B | |
-4.19 | $782.51M | |
-6.17 | $1.63B | |
-13.31 | $6.99B | |
-3.95 | $900.21M | |
-3.48 | $312.42M | |
-0.89 | $153.35M | |
-32.10 | $5.59B | |
-17.73 | $8.19B | |
-5.83 | $839.88M | |
-18.15 | $2.11B | |
-3.26 | $708.49M | |
-4.95 | $115.27M | |
-0.18 | $17.85M | |
-0.58 | $59.36M | |
-2.55 | $205.87M | |
-18.36 | $3.06B | |
14.97 | $2.44B | |
-17.02 | $2.14B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Harmony Biosciences Holdings, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Harmony Biosciences Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Harmony Biosciences Holdings, Inc.'s PE Ratio?
How is the PE Ratio calculated for Harmony Biosciences Holdings, Inc. (HRMY)?
What is the highest PE Ratio for Harmony Biosciences Holdings, Inc. (HRMY)?
What is the 3-year average PE Ratio for Harmony Biosciences Holdings, Inc. (HRMY)?
What is the 5-year average PE Ratio for Harmony Biosciences Holdings, Inc. (HRMY)?
How does the current PE Ratio for Harmony Biosciences Holdings, Inc. (HRMY) compare to its historical average?